NASDAQ · AGMB
Healthcare · Biotechnology
$8.84
Up+$0.15 (+1.73%)
Updated Oct 7, 2026, 8:25 AM
SID Score
2.8/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · AGMB
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 6, 2026
AGMB closed at $8.84 after 21 trading sessions, down 40.71% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 6, 2026 | $8.77 | $8.965 | $8.395 | $8.84 | 103.92K |
| Oct 5, 2026 | $8.51 | $8.71 | $7.97 | $8.69 | 129.8K |
| Oct 2, 2026 | $8.65 | $9.34 | $8.00 | $8.56 | 391.63K |
| Oct 1, 2026 | $11.21 | $11.3224 | $8.56 | $8.65 | 639.38K |
| Sep 30, 2026 | $10.62 | $11.36 | $10.575 | $11.10 | 133.71K |
| Sep 29, 2026 | $10.23 | $10.6934 | $10.14 | $10.53 | 113.49K |
| Sep 28, 2026 | $10.51 | $10.535 | $9.865 | $10.21 | 147.16K |
| Sep 25, 2026 | $10.65 | $11.23 | $10.41 | $10.51 | 164.03K |
| Sep 24, 2026 | $10.75 | $10.99 | $10.50 | $10.58 | 64.17K |
| Sep 23, 2026 | $11.54 | $11.80 | $10.64 | $10.765 | 98.69K |
| Sep 22, 2026 | $11.70 | $11.845 | $11.31 | $11.49 | 49.39K |
| Sep 21, 2026 | $12.26 | $12.26 | $11.28 | $11.70 | 85.41K |
| Sep 18, 2026 | $12.26 | $12.99 | $11.60 | $12.17 | 250.67K |
| Sep 17, 2026 | $11.66 | $12.46 | $11.62 | $12.08 | 339.33K |
| Sep 16, 2026 | $12.26 | $12.845 | $11.21 | $11.41 | 120.33K |
| Sep 15, 2026 | $12.31 | $12.915 | $11.61 | $12.16 | 146.34K |
| Sep 14, 2026 | $13.20 | $13.29 | $12.20 | $12.28 | 86.19K |
| Sep 11, 2026 | $14.00 | $14.10 | $12.96 | $13.06 | 196.65K |
| Sep 10, 2026 | $14.91 | $16.40 | $13.75 | $13.94 | 106.93K |
| Sep 9, 2026 | $14.94 | $15.70 | $14.645 | $14.96 | 72.56K |
| Sep 8, 2026 | $15.78 | $16.50 | $14.51 | $14.91 | 260.63K |
The latest Smart Investors Daily articles mentioning AGMB.
Company
Market Activity
Research & News
AGMB research
Company profile and research snapshot.
AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need. Its product candidates are designed to target established pathways and utilize validated modalities, with a focus on addressing limitations associated with prior treatment approaches. The company's pipeline includes small molecule and antibody product candidates aimed at targets associated with fibrotic diseases. Key candidates include Ontunisertib (AGMB-129) and AGMB-447.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 25, 2026 | Piper Sandler | Overweight | — |
| Aug 19, 2026 | Cantor Fitzgerald | Overweight | — |
| Jul 23, 2026 | B. Riley Securities | Buy | — |
| Jun 22, 2026 | HC Wainwright & Co. | Buy | — |
| Mar 3, 2026 | JP Morgan | Overweight | — |
No generated briefing is available yet.
SeekingAlpha · Oct 1, 2026
AgomAb Therapeutics NV (AGMB) Discusses Open-Label Extension Results of Phase IIa STENOVA Study in Fibrosing Crohn's Disease October 1, 2026 8:30 AM...
Benzinga · Oct 1, 2026
Gainers Elutia (NASDAQ:ELUT) stock moved upwards by 17.2% to $0.94 during Thursday's after-market session. The market value of their outstanding shares is at $34.9 million. Intelligent Bio Solutions (NASDAQ:INBS)
Benzinga · Oct 1, 2026
Agomab Therapeutics reports positive 48-week Phase 2a trial data for ontunisertib in patients with fibrostenotic Crohn's disease.
Yahoo · Oct 1, 2026
Investing.com -- Agomab Therapeutics Nv (NASDAQ:AGMB) shares rose 6.3% in premarket trading Thursday following positive topline results from the open-label extension study of its experimental drug ontunisertib for fibrostenosing Crohn's disease.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning AGMB.
